“Oral administration of adenosine is effective for improving metabolic syndrome-related parameters […] [and] may prevent the progression of the metabolic syndrome” – PubMed – NCBI


What CAN’T It Do? 

Just yesterday we shared research that shows Adenosine Monophosphate is beneficial for activating the molecular pathway responsible for energy management: AMPK. Well the good news just keeps rolling in.

To further test the metabolic impact of supplemental AMP, researchers introduced AMP to a group of rats fed a high-fat diet. They found that the groups receiving regular doses of AMP had significant reductions in blood pressure, LDL Cholesterol (bad cholesterol), plasma glucose and insulin levels compared to placebo. Furthermore, levels of urinary 8-OHd, a well-established indicator of oxidative stress, were nearly halved in the AMP groups compared to placebo.

The researchers used rats known as SHRSP (spontaneously hypertensive stroke-prone) because they are known to exhibit spontaneous hypertension, hyperlipidaemia and insulin resistance. The efficacy of AMP in treating these biologically fragile specimens gives promise to the use of AMP as an effective therapy for similarly compromised human patients, such as those suffering from one or more of the following conditions: Obesity, Hypertension, Insulin Resistance/Pre-diabetes, etc.

Br J Nutr. 2010 Jul;104(1):48-55. doi: 10.1017/S0007114510000255. Epub 2010 Feb 23.

Anti-metabolic syndrome effects of adenosine ingestion in stroke-prone spontaneously hypertensive rats fed a high-fat diet. 

Ardiansyah, Shirakawa H, Sugita Y, Koseki T, Komai M.



We have demonstrated previously that both acute and chronic oral administration of adenosine have novel functions such as anti-hypertensive effects and improved hyperlipidaemia in stroke-prone spontaneously hypertensive rats (SHRSP) fed a normal diet. The purpose of the present study was to investigate the effect of adenosine administration on metabolic syndrome-related parameters in SHRSP fed a high-fat diet. Six-week-old rats were divided into three groups, and were administered either water (control) or adenosine (10 or 100 mg/l) for 8 weeks. During this period, the rats had free access to a high-fat diet based on AIN-93M. The results showed that hypertension, plasma lipid, NO, insulin, glucose and urinary 8-hydroxy-2'-deoxyguanosine levels improved significantly in both adenosine groups. The mRNA expression levels of genes involved in anti-oxidative activity and adenosine receptors were also altered in the adenosine groups. Administration of adenosine also increased plasma adiponectin levels, accompanied by upregulation of mRNA expression level of adiponectin and adiponectin receptor 1 in perirenal fat and adiponectin receptor 2 in the liver. In conclusion, oral administration of adenosine is effective for improving metabolic syndrome-related parameters in SHRSP, and accordingly it may prevent the progression of the metabolic syndrome. 

REMEMBER: For the highest quality form of AMP, ask your doctor about MYODEN from Legere Pharmaceuticals.